117 / 374
117
Simposium
zumab in children with severe aller-
gic asthma: a 1-year real life survey.
Eur Respir J. 2013; 42:1224-33.
2.
Lanier B, Bridges T, Kulus M, Taylor
AF, Berhane I, Vidaurre CF. Omali-
zumab for the treatment of exacer-
bations in children with inadequate-
ly controlled allergic (IgE-mediated)
asthma. J Allergy Clin Immunol
2009; 124:1210-6.
3.
Milgrom H, BergerW, Nayak A, et al.
Treatment of childhood asthma with
anti-immunoglobulin E antibody
(omalizumab). Pediatrics 2001; 108:
E36.
4.
Kulus M, Hebert J, Garcia E, Fowl-
er Taylor A, Fernandez Vidaurre C,
Blogg M. Omalizumab in children
with inadequately controlled severe
allergic (IgE-mediated) asthma. Curr
Med Res Opin 2010; 26:1285-93.2.
5.
Busse WW, Morgan WJ, Gergen
PJ, et al. Randomized trial of omal-
izumab (anti-IgE) for asthma in in-
ner-city children. N Engl J Med 2011;
364:1005-15.
6.
Normansell R, Walker S, Milan SJ,
Walters EH, Nair P. Omalizumab for
asthma in adults and children. Co-
chrane Database Syst Rev. 2014 Jan
13; 1:CD003559.
7.
Global Initiative for Asthma. Global
strategy for asthma management
and prevention 2014. Available from
www.ginasthma.org.
0.22 (0.03-0.41) per year, - 83% of the rate
observed during the first year (p=0.0001).
No hospitalizations for exacerbation were
recorded.We observed a non-significant im-
provement in the level of control with 80%
well-controlled, 15% partially-controlled and
5% uncontrolled patients (p=0.17). At the
end of the second year, the mean daily ICS
dose remained similar at 429 µg (350-509)
per day (p=1). No patients discontinued ICS
treatment. However, 45 patients (63%) bene-
fited from at least a 50% decrease in the ini-
tial dose. No additional gain in lung function
was seen
.
At the end of 2 years, the FEV
1
was
89.9% PV (86.7-93.0) (p=0.38) and FEF
25-75
71.9% PV (65.7-78.0) (p=0.98).
In conclusion, omalizumab is an effective
add-on therapy in uncontrolled problemat-
ic severe asthmatic and atopic children [7].
Those characterized by high IgE production,
poly-sensitizations and/or food allergy were
revealed to form a subpopulation of true se-
vere asthma, and then good responders to
omalizumab. All in all, the impact of omal-
izumab treatment on the natural history of
severe asthma in children deserves to be
further examined by long-term studies to
define both the criteria for discontinuation
and when to discontinue treatment. Safety
should also be monitored and careful re-
porting to pharmacovigilance of adverse
events needs to be emphasized.
References:
1.
Deschildre A, Marguet C, Salleron J,
Pin I, Rittié JL, et al. Add-on omali-